Futura Medical (LSE:FUM) has announced highly positive early feasibility results for WSD4000, its topical gel candidate for female sexual dysfunction, following a small 12-patient study. The trial demonstrated statistically and clinically meaningful improvements across the Female Sexual Function Index, including measures of arousal, lubrication, pain, orgasm and overall satisfaction, in both pre- and post-menopausal participants.
The data also showed a rapid onset of genital sensation, strong performance across Female Sexual Encounter Profile endpoints and good overall tolerability. Based on these findings, the company plans to advance WSD4000 into further development, including a sham- or placebo-controlled sensory study and a larger 200-subject home-use trial during 2026. If successful, this programme could support the development of what Futura believes may become the first regulatory-approved, over-the-counter treatment for female sexual dysfunction, addressing a large and historically underserved global market.
From an investment perspective, the outlook remains constrained by a sharply reduced FY2025 outlook highlighted at the most recent earnings update, alongside a relatively short cash runway and weak technical trend indicators. These risks are partly balanced by the company’s return to profitability in FY2024 and a debt-free balance sheet, although ongoing negative free cash flow continues to temper overall financial quality.
More about Futura Medical
Futura Medical plc is a UK-based consumer healthcare company focused on the research, development and global commercialisation of innovative, topically delivered gel formulations for sexual health. Its lead over-the-counter product, Eroxon, is a topical treatment for erectile dysfunction and is supported by distribution partnerships across major markets including the United States and Europe. The group’s development pipeline includes WSD4000 and Eroxon Intense, targeting unmet needs in female and male sexual dysfunction.
Leave a Reply